Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its anticipated pipeline goals and provided financial guidance for 2013. In the first half of 2013, Infinity expects to report data from both of its wholly owned clinical programs, phosphoinositide-3-kinase (PI3K) and heat shock protein 90 (Hsp90), that will inform potential paths to registration. Each program targets areas of unmet patient need such as advanced hematologic malignancies, inflammatory diseases and non-small cell lung cancer (NSCLC).
“Our pipeline, experienced leadership team and financial position provide the foundation from which we are poised to execute our product development and business strategy as we continue to build a fully integrated biopharmaceutical company,” stated Adelene Q. Perkins, Infinity’s president and chief executive officer. “We have worldwide commercial rights to our entire portfolio of product development candidates and are entering the year with a strong balance sheet that allows us to independently advance our programs while we consider potential partnerships to complement our capabilities.”
Pipeline Expanded with IPI-443, a Potent PI3K-Delta,Gamma Inhibitor
Infinity today also announced its second potent, oral PI3K-delta,gamma inhibitor, IPI-443. Nonclinical studies of IPI-443 are now under way, which are designed to enable the initiation of Phase 1 clinical development.
“PI3K inhibition has therapeutic potential across both hematologic malignancies and inflammatory diseases,” stated Julian Adams, Ph.D., president of R&D at Infinity. “We believe that we have the potential to develop best-in-class PI3K inhibitors and are pleased that IPI-443, our second product candidate targeting PI3K-delta,gamma, has the potential to further maximize our development opportunities across multiple disease pathways and indications.”
2013 Program Goals
Infinity is developing a portfolio of PI3K inhibitors which includes IPI-145 and IPI-443, potent, oral inhibitors of PI3K-delta and PI3K-gamma, as well as retaspimycin hydrochloride (HCl), a potent and selective Hsp90 inhibitor. Infinity anticipates achieving the following development milestones in 2013:
IPI-145 in Hematologic Malignancies
IPI-145 in Inflammation
- 1H2013: Initiate up to five cohort expansions in the ongoing Phase 1 trial in patients with advanced hematologic malignancies
- 1H2013: Define the recommended Phase 2 dose
- 2013: Initiate at least two additional trials
PI3K Pipeline Expansion
- 1H2013: Initiate a Phase 2 trial in patients with rheumatoid arthritis
- 2H2013: Provide update on Phase 2a trial in patients with mild, allergic asthma
Retaspimycin HCl in NSCLC
- 2H2013: Complete nonclinical studies of IPI-443 to enable Phase 1 development
2013 Financial Guidance
- 1H2013: Report topline overall survival data from Phase 2 trial in combination with docetaxel
- 1H2013: Provide update on Phase 1b/2 trial in combination with everolimus
Infinity entered 2013 with approximately $327 million in cash and investments (unaudited). The company is providing the following guidance with respect to its 2013 financial outlook:
Infinity to Present at J.P. Morgan 31
Annual Healthcare Conference
- Operating Expenses: Infinity expects operating expenses for 2013 to range from $115 million to $125 million.
- Net Loss: Infinity expects net loss for 2013 to range from $115 million to $125 million .
- Cash and Investments: Infinity expects to end 2013 with a year-end cash and investments balance ranging from $210 million to $220 million. Based on its current operating plan and exclusive of any business development activities, Infinity’s financial foundation provides a cash runway into 2015.
Infinity will present at the J.P. Morgan 31
Annual Healthcare Conference in San Francisco on Monday, January 7, 2013 at 10:00 a.m. PT (1:00 p.m. ET). A live webcast of Infinity’s presentation will be accessible on the “investors/media” section of the company’s website,
. The presentation will be archived for 30 days following the event.
About Infinity’s PI3K Program
IPI-145 and IPI-443 are potent, oral inhibitors of Class I phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. Infinity believes IPI-145 is the most advanced PI3K-delta,gamma inhibitor in clinical development. The PI3Ks are a family of enzymes involved in multiple cellular functions, including cell proliferation and survival, cell differentiation, cell migration and immunity.
The PI3K-delta and PI3K-gamma isoforms are preferentially expressed in leukocytes, where they have distinct and non-overlapping roles in immune cell development and function. Targeting PI3K-delta and PI3K-gamma may provide multiple opportunities to develop differentiated therapies for the treatment of inflammatory diseases as well as hematologic malignancies.
IPI-145 is currently progressing in a Phase 1 trial in patients with advanced hematologic malignancies. Preliminary data from this trial showed that IPI-145 was well tolerated to date and clinically active in patients with both B-cell and T-cell malignancies, including chronic lymphocytic leukemia, indolent non-Hodgkin’s lymphoma, mantle cell lymphoma, Hodgkin’s lymphoma and T-cell lymphoma.
Infinity is also conducting a Phase 2a trial in patients with mild, allergic asthma and is planning to begin a Phase 2 trial of IPI-145 in patients with rheumatoid arthritis in the first half of 2013.
About Infinity’s Hsp90 Program
Retaspimycin HCl is an intravenously administered, potent and selective heat shock protein 90 (Hsp90) inhibitor. The Hsp90 chaperone plays a key role in regulating the stability of its client proteins.
Cancer cells express elevated levels of Hsp90 relative to normal cells and depend on Hsp90 to support certain oncoproteins and to buffer cellular stresses induced by malignant transformation.
Thus, Hsp90 is a fundamental hub in protein interaction networks, maintaining the functional state of many proteins critical for cancer growth, proliferation and survival.
Inhibition of Hsp90 has the potential to shut down multiple oncogenic signaling pathways simultaneously.
Infinity has completed patient enrollment in a double-blind, randomized, placebo-controlled Phase 2 trial designed to evaluate the anti-tumor activity, tolerability and safety of retaspimycin HCl in combination with docetaxel compared to docetaxel alone in patients with second- or third-line non-small cell lung cancer (NSCLC) who are naïve to docetaxel treatment and have a smoking history. This study is supported by data from a Phase 1b trial in which retaspimycin HCl in combination with docetaxel was well tolerated and clinically active in heavily pretreated patients with NSCLC.
A Phase 1b/2 trial of retaspimycin HCl in combination with everolimus in NSCLC patients with a KRAS mutation is also ongoing.
About Infinity Pharmaceuticals, Inc.
Infinity is an innovative drug discovery and development company seeking to discover, develop and deliver to patients best-in-class medicines for diseases with significant unmet need. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. Infinity’s programs focused on the inhibition of phosphoinositide-3-kinase and heat shock protein 90 are evidence of its innovative approach to drug discovery and development.